Systemic anticancer therapy near the end of life
An analysis of factors influencing treatment in advanced tumor disease
Recent publication
The Divisions of Internal Medicine 2 and Pneumology have collected data from 685 patients at Krems University Hospital who had a solid tumour and died between 2017 and 2021. The use of systemic cancer therapy within the last 30 days of life was analysed. The study hihglights the complexity of treatment decisions and identifies factors to improve patient care. The work was supported by KL as part of the seed funding project ‘Systemic antitumour therapy at the end of life’ and through open access funding and has been published in ‘ESMO Open’.
Le, N-S, Zeybek, A, Hackner, K, Gottsauner-Wolf, S, Groissenberger, I, Jutz, F, Tschurlovich, L, Schediwy, J, Singer, J & Kreye, G 2024, 'Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced tumor disease', ESMO Open, vol. 9, no. 9, 103683, pp. 103683. https://doi.org/10.1016/j.esmoop.2024.103683
OA Dr. Nguyen-Son Le
Division of Internal Medicine 2 (University Hospital Krems)
OA Clin. Ass. Prof. DDr. Klaus Hackner MSc
Division of Pneumology (University Hospital Krems)
Prim. Clin. Assoc. Prof. PD Dr. Josef Singer MBA PhD
Division of Internal Medicine 2 (University Hospital Krems)
OÄ PD Dr. Gudrun Kreye MBA
Division of Internal Medicine 2 (University Hospital Krems)
